Toronto Dominion Bank Boosts Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Toronto Dominion Bank lifted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 3,791.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 997,053 shares of the company's stock after acquiring an additional 971,431 shares during the period. Toronto Dominion Bank owned 0.80% of Apellis Pharmaceuticals worth $31,816,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in APLS. Boxer Capital Management LLC acquired a new stake in Apellis Pharmaceuticals during the 4th quarter valued at approximately $45,504,000. National Bank of Canada FI raised its holdings in shares of Apellis Pharmaceuticals by 266,361.5% during the fourth quarter. National Bank of Canada FI now owns 1,385,600 shares of the company's stock worth $44,214,000 after purchasing an additional 1,385,080 shares during the last quarter. Royal Bank of Canada lifted its position in Apellis Pharmaceuticals by 969.6% during the fourth quarter. Royal Bank of Canada now owns 1,518,827 shares of the company's stock valued at $48,465,000 after purchasing an additional 1,376,832 shares during the period. Cibc World Markets Corp purchased a new stake in Apellis Pharmaceuticals in the fourth quarter valued at $41,014,000. Finally, Point72 Asset Management L.P. purchased a new stake in Apellis Pharmaceuticals in the fourth quarter valued at $40,461,000. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ:APLS traded up $0.61 during trading on Thursday, reaching $17.41. The stock had a trading volume of 1,869,355 shares, compared to its average volume of 2,271,363. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. Apellis Pharmaceuticals, Inc. has a 1-year low of $16.10 and a 1-year high of $43.76. The stock has a market cap of $2.19 billion, a PE ratio of -8.58 and a beta of 0.73. The business has a fifty day moving average price of $19.18 and a 200-day moving average price of $26.10.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $149.90 million for the quarter, compared to analyst estimates of $197.61 million. During the same period last year, the firm earned ($0.54) EPS. The company's revenue for the quarter was down 3.2% compared to the same quarter last year. On average, equities analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on APLS shares. Royal Bank of Canada reduced their price objective on Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating for the company in a research note on Thursday, May 8th. Citigroup reduced their price target on Apellis Pharmaceuticals from $49.00 to $41.00 and set a "buy" rating for the company in a research report on Thursday, May 22nd. Wedbush lowered their price objective on Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. The Goldman Sachs Group dropped their price objective on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. Finally, Bank of America lowered shares of Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their target price for the company from $41.00 to $23.00 in a report on Friday, May 9th. Nine investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $39.89.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the transaction, the general counsel now owns 138,730 shares of the company's stock, valued at approximately $3,482,123. The trade was a 3.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 6.50% of the company's stock.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).